Clinical trials: PET-CT
Urothelial Carcinoma
18F-LN1 PET/CT in Urothelial Carcinomas
The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18F-FDG.
- Trial name
- NCT06120413
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Provincial People's Hospital
Ovarian Cancer, Primary Peritoneal Cancer
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00959582
- Testing
- Comparator: 18-F-FDG PET/CT and Volumetric CT
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Medullary Thyroid Carcinoma
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
This study explores the clinical application of 68Ga-DOTA-CCK-FS PET/CT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof.
- Trial name
- NCT07138716
- Testing
- 68Ga-DOTA-CCK-FS PET/CT
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Luo Yaping
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese…
- Conditions
- Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
- Trial name
- ZIRDOSE-CP (NCT05861778)
- Testing
- 89Zr-Girentuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Prostate Cancer
Evaluation of the Predictive Role of Choline PET/CT on the Survival of Patients Affected by Prostate Cancer.
the increase in the serum PSA (prostate specific antigen) value following radical treatment commonly involves subsequent treatment which, in the absence of morphological evidence of disease recovery, is conducted empirically…
- Trial name
- NCT06158178
- Testing
- Diagnostic accuracy
- Where
- Italy
- Volunteers
- 520 people
- Sponsor
- IRCCS San Raffaele
Neuroendocrine Neoplasm
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in…
- Trial name
- NCT03511768
- Testing
- 18F-AlF-NOTA-octreotide, PET/CT
- Where
- China
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Malignant Neoplasm
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.
- Trial name
- NCT06438250
- Testing
- 68Ga-JH04
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Colon Cancer
18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer.
- Trial name
- COLOPET1 (NCT01636674)
- Testing
- 18F-fluordeoxyglucose positron emission tomography/ computed tomography
- Volunteers
- 66 people
- Sponsor
- Naestved Hospital
Giant Cell Arteritis, Large Vessel Giant Cell Arteriitis
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Longitudinal imaging in patients with large vessel vasculitis to predict further disease course
- Trial name
- NCT04204876
- Testing
- Magnet Resonance Imaging (MRI), PET/CT analysis
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
Uterine Cancer
[18F]FES PET/.CT in Uterine Cancer
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the…
- Trial name
- NCT05916196
- Testing
- 18F-Fluoroestradiol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Comprehensive Assessment of Cancer Theranostic Response
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study.
- Trial name
- TRAQinform (NCT06815354)
- Testing
- TRAQinform Theranostics
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- AIQ Solutions
Prostate Cancer Patients
C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer
Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease planning to undergo Ra-223 therapy may be eligible for this study.
- Trial name
- NCT02715583
- Testing
- 11C-Acetate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Alzheimer's Disease
[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
To investigate the primary brain regions of precursors of Alzheimer's disease and Alzheimer's disease by novel molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT imaging.
- Trial name
- NCT06833645
- Testing
- molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Squamous Cell Carcinoma of the Head and Neck
Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection
Early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract.
- Trial name
- TEPVAD (NCT02510872)
- Testing
- 18F-FDG PET combined with CT with iodinated contrast injection, 18F-FDG PET combined with CT without injection
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Caen
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen
Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer
The purpose of this study is to analyze heterogeneity of prostate cancer（PCa）based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed…
- Conditions
- Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen, Positron Emission Tomography (PET)
- Trial name
- NCT06919159
- Testing
- PSMA PET/CT scan, FDG-PET
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiequn Yu
Tuberculosis, Pulmonary
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in…
- Trial name
- StatinTB (NCT04147286)
- Testing
- Atorvastatin 40mg
- Where
- South Africa
- Volunteers
- 220 people
- Sponsor
- University of Cape Town
Neuroendocrine Tumors (NET)
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging [including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available]
- Trial name
- NCT05673031
- Testing
- 68Ga-HA-DOTATATE PET/CT imaging
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Alberta Health services
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.